Skip Nav Destination
Issues
ARTICLE
Preclinical Evaluation of Amino Acid Prodrugs of Novel Antitumor 2-(4-Amino-3-Methylphenyl)Benzothiazoles 1
Tracey D. Bradshaw; Michael C. Bibby; John A. Double; Iduna Fichtner; Patricia A. Cooper; Michael C. Alley; Susan Donohue; Sherman F. Stinson; Joseph E. Tomaszewjski; Edward A. Sausville; Malcolm F. G. Stevens
Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft
Françoise Kraeber-Bodéré; Catherine Saï-Maurel; Loïc Campion; Alain Faivre-Chauvet; Eric Mirallié; Michel Chérel; Stéphane Supiot; Jacques Barbet; Jean-François Chatal; Philippe Thédrez
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.